スポンサーサイト

上記の広告は1ヶ月以上更新のないブログに表示されています。
新しい記事を書く事で広告が消せます。


Cancer Topics Index 05/06/2016(Daily Test version/ 日刊テスト版)No.25

konpas.jpg
Cancer Topics Index 05/06/2016(Daily Test version/ 日刊テスト版) No.25

Flags 【海外:overseas】
logo-clinicaltrials-gov.png
rinnsyo1.jpg
※2週間前の情報を基準として掲載。一部の記事(がんと直接関連しないもの)は割愛しています。
17 studies found for: cancer | received from 04/22/2016 to 04/22/2016

【前立腺がん】
1 Recruiting
Fusion Guided Focal Laser Ablation of Prostate Cancer
Conditions: Prostate Cancer; Prostate Neoplasms
Intervention: Device: 1.2.Laser Ablation Device
Sponsor:National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:NCT02759744

【がん】
2 Not yet recruiting
Potlako: A Programmatic Intervention to Improve Access to Timely Oncology Care
Conditions: Neoplasms; HIV; Healthcare Disparity
Intervention: Other: Potlako intervention
Sponsor:Harvard School of Public Health
ClinicalTrials.gov Identifier:NCT02752061

【膀胱がん】
3 Not yet recruiting
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
Condition: Urinary Bladder Neoplasms
Intervention: Procedure: Cryoablation
Sponsor:Huashan Hospital
ClinicalTrials.gov Identifier:NCT02760953

【卵巣がん】
4 Not yet recruiting
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Anetumab ravtansine (BAY94-9343); Drug: Pegylated Liposomal Doxorubicin
Sponsor:Bayer
ClinicalTrials.gov Identifier:NCT02751918

【乳がん/センチネルリンパ節】
5 Not yet recruiting
Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy
Condition: Breast Cancer
Intervention: Procedure: Axillary Lymph Node Sampling Clip
Sponsor:Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:NCT02752009

【非小細胞肺がん】
6 Not yet recruiting
A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus
Condition: Non-Small Cell Lung Cancer
Interventions: Radiation: Conventional radiotherapy; Radiation: Esophageal-Sparing Intensity-Modulated Radiotherapy
Sponsor:Lawson Health Research Institute
ClinicalTrials.gov Identifier:NCT02752126

【乳がん】
7 Recruiting
Developing a New Questionnaire About Patient Expectations of Breast Conserving Therapy
Condition: Breast Cancer
Interventions: Behavioral: qualitative interviews with patients; Behavioral: questionnaires
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02753673

【固形腫瘍】
8 Not yet recruiting
A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers
Condition: Malignant Solid Tumor
Interventions: Biological: BMS-986179; Biological: Nivolumab
Sponsor:Bristol-Myers Squibb
ClinicalTrials.gov Identifier:NCT02754141

【乳がん】
9 Completed
Pilot Study for a Prospective Surveillance Program for Rehabilitation Following Surgery for Breast Cancer
Condition: Breast Cancer
Interventions: Behavioral: Prospective Surveillance Group; Behavioral: Education Group
Sponsor:University of British Columbia
ClinicalTrials.gov Identifier:NCT02754427

【神経膠腫】
10 Completed
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
Condition: Brain Neoplasm
Intervention: Biological: Gliolan
Sponsor:medac GmbH
ClinicalTrials.gov Identifier:NCT02755142

【非小細胞肺がん】
11 Not yet recruiting
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Microgynon; Drug: Nintedanib
Sponsor:Boehringer Ingelheim
ClinicalTrials.gov Identifier:NCT02751385

【卵巣がん/高異型漿液性腺がん】
12 Not yet recruiting
Proof-of-concept Study of Birinapant in Combination With Platinum Based Chemotherapy in Subjects With High Grade Serous Carcinomas
Condition: Advanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC)
Interventions: Drug: Birinapant; Drug: Paclitaxel; Drug: Carboplatin
Sponsor:Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:NCT02756130

【上咽頭がん】
13 Recruiting
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
Condition: Cancer
Intervention: Drug: ARGX-110
Sponsor:arGEN-X BVBA
ClinicalTrials.gov Identifier:NCT02759250

【非小細胞肺がん】
14 Not yet recruiting
Real World Data on Gi(l)Otrif® Dose Adjustment
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Gi(l)otrif®
Sponsor:Boehringer Ingelheim
ClinicalTrials.gov Identifier:NCT02751879

【急性骨髄性白血病(AML)/急性リンパ芽球性白血病(ALL)】
15 Recruiting
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias
Conditions: Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Procedure: Haploidentical Stem Cell Transplantation
Sponsor:Leonardo Javier Arcuri
ClinicalTrials.gov Identifier:NCT02759822

【急性骨髄性白血病(AML)】
16 Not yet recruiting
A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Conditions: Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Interventions: Drug: ASP2215; Drug: Azacitidine
Sponsor:Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier:NCT02752035

【黒色腫】
17 Not yet recruiting
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: pembrolizumab + epacadostat; Drug: pembrolizumab + placebo
Sponsor:Incyte Corporation
ClinicalTrials.gov Identifier:NCT02752074

animated-european-union-flag.gif
◇EU, EMA, CHMP, Cancer Research UK, NICE◇
pexels-photo-25516-hero.jpg
【がんの旅】
A JOURNEY THROUGH CANCER (05/05/2016 Cancer Research UK)
Everyone’s journey through cancer is different.Here we try to portray the experience through the words of those who know it best.This article has been drawn together from the memories, reflections and stories that patients have shared with us.By sharing these stories, we hope to show a little of what it can be like to go through cancer.

<Medical Journal & Other News>
headline.jpg
【黒色腫/免疫チェックポイント療法の応答を予測できるタンパク質 Bim】JOURNAL:JCI Insight
Protein may predict response to immunotherapy in patients with metastatic melanoma (05/05/2016 EurekAlert!/MAYO CLINIC)
ROCHESTER, Minn. -- A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., Ph.D., and published online in the May 5 edition of JCI Insight."Immune checkpoint therapy with PD-1 blockade has emerged as an effective treatment for many advanced cancers," says the study's lead author, Roxana Dronca, M.D., an oncologist at Mayo Clinic. "However, only a fraction of patients achieve durable responses to immunotherapy and, to date, we have had no means of predicting which patients are most likely to benefit."

【肺がん/4つのPD-L1アッセイの分析】2016 Annual Meeting of the American Association for Cancer Research (AACR)
Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released (05/05/2016 EurekAlert!/INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER)
DENVER - A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the "BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT" at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19. The study compared four PD-L1 IHC diagnostic assays developed in conjunction with four PD-1/PD-L1 immune checkpoint inhibitors, which are used in non-small cell lung cancer (NSCLC) clinical trials.

【神経障害性疼痛を低減】JOURNAL:Cell Reports
Research findings reveal potential to reverse cancer-related nerve pain (05/05/2016 EurekAlert!/UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER)
A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment.The study in rats showed transfer of a gene known as KCC2 into the spinal canal restored chloride levels gone awry after nerve injury. Results from the research at The University of Texas MD Anderson Cancer Center, were published in the May 5 online issue of Cell Reports.

【卵巣がん/治療標的 miR551b】JOURNAL:Cell Reports
Study points to therapeutic target for common and aggressive ovarian cancer (05/05/2016 EurekAlert!/UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER)
Small, non-coding molecules called microRNAs are known to play an important role in cancer development. Researchers now have shown their significance is greater than previously thought, a finding that could lead to new therapeutic approaches for the most common and deadly form of ovarian cancer.The study results, published in the May 5 online issue of Cell Reports, were reported by a team led by Gordon Mills, Ph.D., chair of Systems Biology at The University of Texas MD Anderson Cancer Center.

【医療ミス】
Study Suggests Medical Errors Now Third Leading Cause of Death in the U.S. (May 3, 2016  The Johns Hopkins University)
医療ミス、米国で死因3位 研究 (05/05/2016 AFPBB:日本語)
Analyzing medical death rate data over an eight-year period, Johns Hopkins patient safety experts have calculated that more than 250,000 deaths per year are due to medical error in the U.S. Their figure, published May 3 in The BMJ, surpasses the U.S. Centers for Disease Control and Prevention’s (CDC’s) third leading cause of death — respiratory disease, which kills close to 150,000 people per year.The Johns Hopkins team says the CDC’s way of collecting national health statistics fails to classify medical errors separately on the death certificate. The researchers are advocating for updated criteria for classifying deaths on death certificates.

Graphics 【日本国内:Japan】
<Press Release:日本国内>
<News>
【副作用】
抗がん剤の副作用 免疫力の低下や味覚障害など (05/06/2016 NEWSポストセブン)

【一部助成】
横浜市 がん患者に生活支援 かつら購入など一部助成 (05/05/2016 タウンニュース)

<雑誌記事:Magazine/Medical journal>
Stockholm Public Library
◆先見経済 (2016年5月号)/清話会/発売日:2016年5月5日/価格(税込):3,240円
【タイトル】清話会セミナー講演録
・進化し続けるガン治療最前線 筑間晃比古

スポンサーサイト

Cancer Topics Index 05/05/2016(Daily Test version/ 日刊テスト版)No.24

konpas.jpg
Cancer Topics Index 05/05/2016(Daily Test version/ 日刊テスト版) No.24

Flags 【海外:overseas】
◇NCI (National Cancer Institute)◇
【5月の新情報】(website)
New on NCI’s Websites for May 2016 (May 2, 2016 by NCI Staff)
・【切除不能脊索腫のためのワクチン療法】
 Vaccine Therapy for Unresectable Chordoma
・【子供ががん治療を受けている両親・兄弟のための情報】
 Parents Who Have a Child with Cancer
・【がんの発生率、死亡率、生存率、罹患率、および生涯リスクなどの最新疫学データ】
 SEER Data, 1973-2013
・【がん顕微鏡画像の公共データ】
Dividing Breast Cancer Cell
 NCI Cancer Close Up 2016 Collection Gallery 
・【腎臓・腎盂がんのこと知っていますか?】
 Kidney and Renal Pelvis Cancer | Did You Know?

・【新薬情報】
 Melphalan (多発性骨髄腫、上皮性卵巣がん)
 Melphalan Hydrochloride (多発性骨髄腫)
 Defibrotide Sodium (幹細胞移植後の肝静脈閉塞性疾患)
 Venetoclax (慢性リンパ球性白血病[CLL])
・【リラックス】
 Learning to Relax
 (がん患者のためのリラックス術)
・【PDQ要約を更新】
 ・Bladder and Other Urothelial Cancers Screening–Health Professional Version (PDQ®)
 (膀胱およびその他の尿路上皮がんのスクリーニング)
 ・Cancer Screening Overview–Health Professional Version (PDQ®)
 (がん検診の概要)
 ・Childhood Acute Lymphoblastic Leukemia Treatment–Health Professional Version (PDQ®)
 (小児急性リンパ性白血病の治療)
 ・Childhood Soft Tissue Sarcoma Treatment–Health Professional Version (PDQ®)
 (子供の頃軟部組織肉腫の治療)
 Last Days of Life–Health Professional Version (PDQ®)
 (人生の最後の日)
 ・Late Effects of Treatment for Childhood Cancer–Health Professional Version (PDQ®)
 (小児がん治療の晩期)
 ・Melanoma Treatment–Health Professional Version (PDQ®)
 (メラノーマの治療)
 ・Oral Cavity and Oropharyngeal Cancer Screening–Health Professional Version (PDQ®)
 (口腔および咽頭がんのスクリーニング)
 ・Prostate Cancer, Nutrition, and Dietary Supplements–Health Professional Version (PDQ®)
 (前立腺がん、栄養、そしてサプリメント)
 ・Topics in Integrative, Alternative, and Complementary Therapies–Health Professional Version (PDQ®)
 (統合・代替および相補療法におけるトピックス)

logo-clinicaltrials-gov.png
rinnsyo1.jpg
※2週間前の情報を基準として掲載。一部の記事(がんと直接関連しないもの)は割愛しています。
6 studies found for: cancer | received from 04/21/2016 to 04/21/2016

【トリプルネガティブ乳がん】
1 Not yet recruiting
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Conditions: Breast Cancer; Early Stage; Triple Negative Breast Cancer
Interventions: Drug: Enzalutamide; Behavioral: assessment
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02750358

【大腸がん】
2 Completed
The Feasibility of an Active Lifestyle Programme in Patients Recovering From Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Behavioral: Active lifestyle programme
Sponsor:University of East Anglia
ClinicalTrials.gov Identifier:NCT02751892

【唾液腺がん】
3 Not yet recruiting
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Condition: Salivary Cancer
Intervention: Drug: enzalutamide
Sponsor:Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:NCT02749903

【がん】
4 Not yet recruiting
Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients
Condition: Cancer
Interventions: Other: Reflexology; Other: Meditative Practices
Sponsor:Michigan State University
ClinicalTrials.gov Identifier:NCT02759146

【非小細胞肺がん】
5 Not yet recruiting
A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer
Condition: Advanced Cancer
Interventions: Biological: Nivolumab; Drug: Dasatinib; Biological: BMS-986016
Sponsor:Bristol-Myers Squibb
ClinicalTrials.gov Identifier:NCT02750514

【急性骨髄性白血病】
6 Not yet recruiting
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: Cladribine; Drug: Cytarabine; Biological: Filgrastim; Drug: Fludarabine Phosphate; Procedure: Hematopoietic Cell Transplantation; Drug: Melphalan; Drug: Methotrexate; Drug: Mitoxantrone Hydrochloride; Drug: Mycophenolate Mofetil; Other: Questionnaire Administration; Drug: Tacrolimus
Sponsor:University of Washington
ClinicalTrials.gov Identifier:NCT02756572

<Medical Journal & Other News>
headline.jpg
【口腔がん/生存率の予測可能ながん遺伝子】JOURNAL:Otolaryngology-Head and Neck Surgery
Discovery of cancer gene may predict survival in patients with mouth cancers (05/04/2016 EurekAlert!/LOYOLA UNIVERSITY HEALTH SYSTEM)
MAYWOOD, IL - Loyola researchers have identified a tumor gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue.If the gene is expressed (turned on), patients are 4.6 times more likely to die at any given time, according to a study by researchers at Loyola Medicine and Loyola University Chicago Stritch School of Medicine.

【大腸がん・大腸炎/O-グリカン糖の生成と治療法へのアプローチ】JOURNAL:Gastroenterology
Findings light the way for new treatments in colitis, colon cancer (05/04/2016 EurekAlert!/OKLAHOMA MEDICAL RESEARCH FOUNDATION)
An Oklahoma Medical Research Foundation scientist has discovered that certain sugars produced by the body play an important role in the development of colitis and, ultimately, colon cancer. The new finding could potentially lead to therapies for ulcerative colitis, Crohn's disease and colon cancer.At OMRF, Lijun Xia, M.D., Ph.D., has spent two decades studying O-glycans, a form of sugar that the body produces and that comprises nearly 80 percent of a thick mucous layer inside the colon and the gastrointestinal tract.

【膵臓がん】JOURNAL:Diabetes, obesity & metabolism
Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.(PubMed/Diabetes Obes Metab. 2016 Mar)
糖尿病の人に頻発する膵臓がんは薬の副作用か? 18万人のデータ解析から (05/04/2016 MEDLEY:日本語)

Graphics 【日本国内:Japan】
<News>
【がんの血液検査】
がんの血液検査には「有害無益」な項目がある 「早期発見」の声に流されず、賢い選択を! 高野 利実 :虎の門病院臨床腫瘍科部長 (05/03/2016 東洋経済Online)

【胃がん検診】
50歳以下の人には必要ない毎年の胃がん検診 内視鏡検査を選択肢に加え、50歳以上、2年に1回にするべき 多田 智裕・ただともひろ胃腸肛門科院長(05/02/2016 JBpress)

<新刊メタデータ:New Books>
book_sepia.jpg
【タイトル】液状化検体細胞診断マニュアル
監修:佐々木 寛/畠 榮, 則松 良明, 亀井 敏昭, 金城 満(編集)/大型本: 305ページ/出版社: 篠原出版新社 (2016/05)/ISBN-10: 4884123905/ISBN-13: 978-4884123901/¥10,800

Cancer Topics Index 05/04/2016(Daily Test version/ 日刊テスト版)No.23

konpas.jpg
Cancer Topics Index 05/04/2016(Daily Test version/ 日刊テスト版) No.23

Flags 【海外:overseas】
◇NIH (National Institutes of Health)◇
capsule2-guide-for-parents-img.jpg
【小児がん/親のためのガイド】
Children with Cancer: A Guide for Parents (May 2016 NIH News in Health)
ダウンロードサイト (84ページのブックレットです)pdf_dl.png

【家族のための小児の緩和ケア/ナビゲーション】
NIH resources to help families navigate pediatric palliative care (May 3, 2016 NIH News Release)
Palliative Care: Conversations (website)

【ニューイングランド/井戸水中のヒ素による膀胱がんリスクの上昇】
Elevated bladder cancer risk in New England and arsenic in drinking water from private wells (May 2, 2016 NIH News Release)

logo-clinicaltrials-gov.png
rinnsyo1.jpg
※2週間前の情報を基準として掲載。一部の記事(がんと直接関連しないもの)は割愛しています。
20 studies found for: cancer | received from 04/20/2016 to 04/20/2016

【乳がん】
1 Recruiting
Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Condition: HR+ HER2- Postmenopausal Advanced Breast Cancer
Interventions: Drug: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant; Drug: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
Sponsor:Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:NCT02753686

【大腸がん】
2 Recruiting
Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical
Condition: Colorectal Neoplasms
Interventions: Drug: Two Anti-angiogenesis Drugs(Endostar and Thalidomide); Drug: Pure chemotherapy(Xelox)
Sponsor:The First People's Hospital of Hefei
ClinicalTrials.gov Identifier:NCT02748772

【乳がん】
3 Recruiting
Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: 68Ga-NOTA-BBN-RGD
Sponsor:Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:NCT02749019

【子宮頸がん】
4 Not yet recruiting
Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner
Conditions: Malignant Tumor of Cervix; Cervical Intraepithelial Neoplasia
Intervention: Device: Vaginal self-sampling brush
Sponsor:University Hospital, Lille
ClinicalTrials.gov Identifier:NCT02749110

【膀胱がん】
5 Active, not recruiting
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
Condition: Bladder Cancer
Intervention:
Sponsor:Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier:NCT02756637

【下垂体腫瘍】
6 Not yet recruiting
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
Conditions: Pituitary Tumor; ACTH-producing Pituitary Tumour
Intervention: Drug: Pasireotide LAR
Sponsor:Columbia University
ClinicalTrials.gov Identifier:NCT02749227

【乳がん】
7 Completed
A Study of Trastuzumab (Herceptin) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Capecitabine; Drug: Docetaxel; Drug: Trastuzumab
Sponsor:Hoffmann-La Roche
ClinicalTrials.gov Identifier:NCT02748213

【がん】
8 Not yet recruiting
Imaging NSCLC Treatment Response to Immunotherapy
Condition: Cancer
Interventions: Other: Imaging - DW-MRI; Radiation: FDG PET-CT
Sponsor:Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier:NCT02753569

【卵巣がん/認知障害】
9 Recruiting
Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian Cancer
Conditions: Cognition Disorders; Polyneuropathies
Intervention: Drug: paclitaxel/ carboplatin chemotherapy
Sponsor:Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:NCT02753036

【がん】
10 Not yet recruiting
A Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1(Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies
Conditions: Carcinoma, Non-small-cell Lung; Mesothelioma; Pancreatic Neoplasms
Interventions: Drug: Defactinib; Drug: Pembrolizumab
Sponsor:NHS Greater Glasgow and Clyde
ClinicalTrials.gov Identifier:NCT02758587

【脳転移】
11 Recruiting
Whole Brain Radiation Using IMRT for Patients With Brain Metastases
Conditions: Neoplasm Metastasis; Central Nervous System Metastases
Intervention: Radiation: Intensity Modulated Radiotherapy
Sponsor:New Mexico Cancer Care Alliance
ClinicalTrials.gov Identifier:NCT02753790

【口腔扁平上皮がん】
12 Recruiting
Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study
Conditions: Oral Squamous Cell Carcinoma; Carcinoma of Buccal Mucosa; Tongue Cancers; Head and Neck Cancers
Interventions: Drug: Celecoxib; Drug: Erlotinib; Drug: Celecoxib + Erlotinib
Sponsor:Tata Memorial Hospital
ClinicalTrials.gov Identifier:NCT02748707

【膵がん】
13 Recruiting
Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes
Condition: Pancreatic Neoplasms
Interventions: Drug: Gemcitabine; Radiation: TS-1 with radiation
Sponsor:Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:NCT02754180

【膵がん】
14 Not yet recruiting
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
Condition: Pancreatic Adenocarcinoma
Intervention: Drug: Preoperative modified FOLFIRINOX and postoperative gemcitabine
Sponsor:Asan Medical Center
ClinicalTrials.gov Identifier:NCT02749136

【下垂体腺腫/記憶障害】
15 Not yet recruiting
Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory
Conditions: Cavernous Sinus Meningioma; Pituitary Adenoma
Intervention: Other: Evaluation of autobiographical memory
Sponsor:University Hospital, Bordeaux
ClinicalTrials.gov Identifier:NCT02750371

【多発性骨髄腫】
16 Not yet recruiting
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: Venetoclax; Drug: Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsor:AbbVie
ClinicalTrials.gov Identifier:NCT02755597

【びまん性大細胞型B細胞性リンパ腫】
17 Not yet recruiting
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Conditions: Diffuse Large B Cell Lymphoma; Primary Mediastinal (Thymic) Large B-cell Lymphoma; Transformed Indolent Lymphoma; Recurrent Disease; Refractory Cancer
Intervention: Drug: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
Sponsor:Meirav Kedmi MD
ClinicalTrials.gov Identifier:NCT02747732

【膀胱がん/疼痛】
18 Active, not recruiting
Persistent Pain After Cystectomy for Bladder Cancer
Conditions: Pain; Surgery; Post Operative Pain
Intervention:
Sponsor:Washington University School of Medicine
ClinicalTrials.gov Identifier:NCT02751346

【扁平上皮がん/基底細胞がん】
20 Not yet recruiting
Intraoperative Margin Assessment During Mohs Surgery
Conditions: Squamous Cell Carcinoma (SCC); Basal Cell Carcinoma (BCC)
Intervention: Device: Multimodal Spectroscopy (MMS)
Sponsor:Seton Healthcare Family
ClinicalTrials.gov Identifier:NCT02750033

【びまん性大細胞型B細胞リンパ腫】
22 Recruiting
Reduced Chemotherapy in Low Risk DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Vincristine; Drug: Prednisone
Sponsor:Ruijin Hospital
ClinicalTrials.gov Identifier:NCT02752815

animated-european-union-flag.gif
◇EU, EMA, CHMP, Cancer Research UK, NICE◇
cell-breast-cancer.jpg
【乳がん/個別化医療】
DNA analysis brings scientists step closer to ‘complete picture’ of breast cancer (3 May 2016 News report:In collaboration with the Press Association)
An analysis of the complete genetic code of hundreds of breast tumours could lead to more personalised care for patients, according to an international team of scientists.The results reveal that patients’ tumours may be highly individual. And experts have said that the new findings offer a more comprehensive view of breast cancer.

<Medical Journal & Other News>
headline.jpg
【コレステロール代謝と膵がんコントロール】JOURNAL:Oncogene
Research points to a new treatment for pancreatic cancer (05/03/2016 EurekAlert!/PURDUE UNIVERSITY)
WEST LAFAYETTE, Ind. -- Researchers have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis, pointing to a potential new treatment using drugs previously developed for atherosclerosis."We show for the first time that if you control the cholesterol metabolism you could reduce pancreatic cancer spread to other organs," said Ji-Xin Cheng, a professor in Purdue University's Weldon School of Biomedical Engineering and Department of Chemistry. "We chose pancreatic cancer to test this approach because it is the most aggressive disease of all the cancers."

【卵巣除去による大腸がんリスクの上昇】JOURNAL:British Journal of Surgery
Ovary removal may increase the risk of colorectal cancer (05/04/2016 EurekAlert!/WILEY)
Colorectal cancer may rise in women who have their ovaries removed, according to new research.The development of colorectal cancer is influenced by hormonal factors, and removal of the ovaries alters a woman's sex hormone levels. Among 195,973 Swedish women who had undergone ovary removal between 1965 and 2011, there was a 30% increase in the rate of colorectal cancer compared with the general population. After accounting for various factors, women who had both ovaries removed had a 2.3-times higher risk of rectal cancer than those who had only one ovary removed.

Graphics 【日本国内:Japan】
<News>
【乳がん】
【がん電話相談から】ルミナールA型乳がん全摘術後抗がん剤治療は? (05/03/2016 産経ニュース)

【乳がん】
乳がん専門医 「告知されたら思い切り悲しんでよい」濱岡ブレストクリニック・濱岡剛院長 (05/03/2016 NEWSポストセブン)

【乳がん】
乳がん経験者の体験談 告知から6年で274万円かかった ファイナンシャルプランナー・黒田尚子さん(05/03/2016 NEWSポストセブン)

【虚偽】
中国当局が百度への調査を開始、同社の検索で得た情報でがん治療を受けた大学生の死亡を受けて―米メディア (05/03/2016 Record china)

【闘病記】
闘病記にはそれほど期待していないんです アピタル・高柳由香 (05/02/2016 朝日新聞デジタルapital)


Cancer Topics Index 05/03/2016(Daily Test version/ 日刊テスト版)No.22

konpas.jpg
Cancer Topics Index 05/03/2016(Daily Test version/ 日刊テスト版) No.22

Flags 【海外:overseas】
logo-clinicaltrials-gov.png
rinnsyo1.jpg
※2週間前の情報を基準として掲載。一部の記事(がんと直接関連しないもの)は割愛しています。
21 studies found for: cancer | received from 04/19/2016 to 04/19/2016

【乳がん/減量】
1 Not yet recruiting
Breast Cancer WEight Loss Study (BWEL Study)
Conditions: Ductal Breast Carcinoma in Situ; Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsor:Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:NCT02750826

【前立腺がん】
2 Recruiting
68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer Patients
Condition: Prostate Cancer
Intervention: Drug: 68Ga-NOTA-BBN-RGD
Sponsor:Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:NCT02747290

【がん】
3 Recruiting
PET Imaging of Patients With Cancer Using 124I-PU-AD
Conditions: Solid Malignancy; Lymphoma; Multiple Myeloma
Interventions: Drug: 124I-PU-AD; Device: PET Scan; Other: Blood draws
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02751554

【転移性乳がん】
4 Not yet recruiting
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Abemaciclib; Drug: Tamoxifen; Drug: Prophylactic Loperamide
Sponsor:Eli Lilly and Company
ClinicalTrials.gov Identifier:NCT02747004

【前立腺がん】
5 Not yet recruiting
Evaluation of PSA Blood Levels Prior to and After Digital Rectal Examination
Condition: Prostate Cancer
Intervention: Other: Blood test (PSA)
Sponsor:Kaplan Medical Center
ClinicalTrials.gov Identifier:NCT02747563

【小児がん/コーチングプログラム】
6 Recruiting
Experiential Training With Healthcare Coaching in Childhood Cancer Patients
Conditions: Child; Neoplasms
Interventions: Behavioral: healthcare professional coaching; Behavioral: Placebo Control
Sponsor:The University of Hong Kong
ClinicalTrials.gov Identifier:NCT02754973

【非小細胞肺がん】
7 Recruiting
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Conditions: Non-small Cell Lung Cancer; Malignant Pleural Mesothelioma; Large Cell Neuroendocrine Carcinoma of the Lung
Intervention: Other: 68Ga-NOTA-AE105 PET/CT
Sponsor:Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:NCT02755675

【黒色腫】
8 Not yet recruiting
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Conditions: Metastatic Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck
Interventions: Biological: Aldesleukin; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab
Sponsor:Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:NCT02748564

【神経膠腫】
9 Not yet recruiting
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Conditions: Astrocytoma; Glioma; Oligodendroglioma
Interventions: Biological: Hepatitis A Vaccine; Other: Laboratory Biomarker Analysis; Biological: Tetanus Toxoid Vaccine; Biological: Trivalent Influenza Vaccine
Sponsor:Comprehensive Cancer Center of Wake Forest University
ClinicalTrials.gov Identifier:NCT02747407

【副腎皮質腫瘍】
10 Not yet recruiting
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
Conditions: Adrenal Cortex Neoplasms; Adrenal Cortex Diseases
Intervention:
Sponsor:Bnai Zion Medical Center
ClinicalTrials.gov Identifier:NCT02747355

【小児固形腫瘍】
11 Not yet recruiting
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Condition: Pediatric Solid Tumors
Interventions: Drug: Sorafenib; Drug: Irinotecan
Sponsor:Washington University School of Medicine
ClinicalTrials.gov Identifier:NCT02747537

【非小細胞肺がん】
12 Not yet recruiting
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Condition: Malignant Non-small Cell Neoplasm of Lung Stage IV
Intervention: Drug: Capmatinib (INC280)
Sponsor:Massachusetts General Hospital
ClinicalTrials.gov Identifier:NCT02750215

【去勢抵抗性前立腺がん】
13 Not yet recruiting
A Trial of SHR3680 in mCRPC
Condition: Neoplasm
Intervention: Drug: SHR3680 oral administration
Sponsor:Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier:NCT02747342

【がん】
14 Not yet recruiting
eRAPID Feasibility Pilot Study in Pelvic Radiotherapy
Condition: Cancer
Intervention: Device: eRAPID
Sponsor:University of Leeds
ClinicalTrials.gov Identifier:NCT02747264

【多形性膠芽腫】
15 Recruiting
Determination of Immune Phenotype in Glioblastoma Patients
Condition: Glioblastoma Multiforme
Intervention: Procedure: Surgery
Sponsor:University of Ulm
ClinicalTrials.gov Identifier:NCT02751138

【肺疾患】
17 Not yet recruiting
Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
Conditions: Lung Transplant; Lung Resection; Lung Cancer; Asthma; Cystic Fibrosis; Chronic Obstructive Pulmonary Disease; Emphysema; Mesothelioma; Asbestosis; Pulmonary Embolism; Interstitial Lung Disease; Pulmonary Fibrosis; Bronchiectasis; Seasonal Allergies; Cold Virus; Lung Infection; Pulmonary Hypertension; Pulmonary Dysplasia; Obstructive Sleep Apnea
Interventions: Drug: HP 3He; Drug: HP 129Xe; Drug: PFP; Drug: SF6; Device: 129Xe Small and Large Human Lung Coil; Device: 3He Human Lung Coil; Device: PFP and SF6 Human Lung Coil
Sponsor:Thunder Bay Regional Research Institute
ClinicalTrials.gov Identifier:NCT02748798

【脳転移】
18 Not yet recruiting
The Clinical Relevance of Margins in Frameless Stereotactic Radiosurgery for Intact Brain Metastases: a Randomized Trial of 0 vs 2 mm Margins
Condition: Brain Metastases
Intervention: Procedure: Stereotactic Radiosurgery
Sponsor:University of Chicago
ClinicalTrials.gov Identifier:NCT02747303

【膵管がん】
20 Recruiting
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Condition: Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Drug: Nivolumab; Drug: Albumin-bound paclitaxel; Drug: Paricalcitol; Drug: Cisplatin; Drug: Gemcitabine
Sponsor:HonorHealth Research Institute
ClinicalTrials.gov Identifier:NCT02754726

【びまん性大細胞型B 細胞リンパ腫】
23 Recruiting
Chidamide Plus R-CHOP in Elderly DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Vincristine; Drug: Prednisone; Drug: Chidamide
Sponsor:Ruijin Hospital
ClinicalTrials.gov Identifier:NCT02753647

【末梢性T細胞リンパ腫】
24 Recruiting
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Chidamide
Sponsor:Ruijin Hospital
ClinicalTrials.gov Identifier:NCT02753543

【非ホジキンリンパ腫】
25 Not yet recruiting
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: ABP 798; Drug: Rituximab
Sponsor:Amgen
ClinicalTrials.gov Identifier:NCT02747043

animated-european-union-flag.gif
◇EU, EMA, CHMP, Cancer Research UK, NICE◇
【再発結腸・直腸がん】
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2016 (26/02/2016 EMA)
LONSURF®(一般名:トリフルリジン・チピラシル)が進行・再発の結腸・直腸がん治療薬として欧州で承認を取得- 欧州の患者さんに新たな治療選択肢を - (04/28/2016 大鵬薬品工業 Taiho Pharmaceutical)

<Medical Journal & Other News>
headline.jpg
【乳がん/5-azacytidine/butyrate therapyで乳がん幹細胞を標的に】JOURNAL:Cancer Research
Two known chemotherapy agents effectively target breast cancer stem cells (05/02/2016 EurekAlert!/MEDICAL COLLEGE OF GEORGIA AT AUGUSTA UNIVERSITY)
AUGUSTA, Ga. - Two existing chemotherapy drugs appear to be a powerful pair in targeting errant stem cells that are making breast cancer and enabling its spread and recurrence, scientists report.A combination of the drugs, 5-azacytidine and the HDAC inhibitor butyrate, reduces the number of cancer stem cells and improves survival in an animal model of breast cancer, they report in the journal Cancer Research. Alone, neither was effective.

【欠陥のある現在の創薬方法に新アプローチ】JOURNAL:Nature Methods
Current cancer drug discovery method flawed: Study (05/02/2016 EurekAlert!/VANDERBILT UNIVERSITY MEDICAL CENTER)
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods. The findings cast doubt on methods used by the entire scientific enterprise and pharmaceutical industry to discover new cancer drugs."More than 90 percent of candidate cancer drugs fail in late stage clinical trials, costing hundreds of millions of dollars," said Vito Quaranta, M.D., director of the Quantitative Systems Biology Center at Vanderbilt. "The flawed in vitro drug discovery metric may not be the only responsible factor, but it may be worth pursuing an estimate of its impact."

Graphics 【日本国内:Japan】
<News>
【陛下のがん】
「天皇陛下の癌」がん告知を主張した医師の遺書 初公開(1)(05/02/2016 デイリー新潮)
陛下にはがん告知はされていなかった がん告知を主張した医師の遺書 初公開(2)(05/02/2016 デイリー新潮)

【DDS】
ナノマシンを用いたがん治療 今年中には実現か? (05/02/2016 EconomicNews)

【乳がん】
12人に1人がかかる乳がん 進行度、悪性度で治療法異なる (05/02/2016 NEWSポストセブン)

【4つの誤解】
がん治療を阻む4つの誤解 偏った情報に惑わされ、正しい判断ができなくなることを避けるには 森山紀之ミッドタウンクリニック 理事 (05/01/2016 日経Goodday)

<雑誌記事:Magazine/Medical journal>
Stockholm Public Library
◆INNERVISION(インナービジョン) (2016年5月号)/インナービジョン/発売日:2016年5月1日/価格(税込):2,376円
【タイトル】特集 マルチモダリティによるAbdominal Imaging 2016
I 肝
1.肝細胞がんの診断  鶴﨑正勝ほか
2.早期肝細胞癌の診断  清水辰哉/本杉宇太郎
3.肝内胆管がんと肝転移の診断  藤田展宏ほか
4.肝良性腫瘤性病変の診断  小林 聡ほか
5.肝細胞がんのIVR治療  宮山士朗

II 胆 道
1.急性胆管炎の診断  小坂一斗ほか
2.胆道良性腫瘍の診断  五島 聡
3.胆道悪性腫瘍疾患の画像診断  牛尾貴輔ほか

III 膵 臓
1.膵悪性腫瘍の診断  望月健太郎ほか
2.膵良性腫瘍の診断  戸島史仁
3.膵嚢胞性腫瘍の診断  入江裕之ほか
4.慢性膵炎(自己免疫性膵炎を含む)の診断  藤永康成ほか

IV 腎・副腎
1.悪性腎腫瘍の診断  秋田大宇/陣崎雅弘
2.良性腎腫瘤および炎症性腎疾患の診断  吉田耕太郎ほか

◆NutritionCare(ニュートリションケア) (2016年5月号)/メディカ出版/発売日:2016年5月1日/価格(税込):1,944円
【タイトル】がん患者の心に寄り添い食べる喜びを支える
・病院給食で対応可能なあっさりとした「だいこんと長いものすりおろし」
 大妻女子大学/島根大学 川口美喜子

◆エルネオス (ELNEOS) (2016年5月号)/エルネオス出版社/発売日:2016年5月1日/価格(税込):853円
【タイトル】医療の現実
・副作用に悩む女性が集団訴訟へ、子宮頸がんワクチンに評価の差

◆モダンフィジシャン(Modern Physician) (2016年No.5)/新興医学出版社/発売日:2016年5月1日/価格(税込):3,024円
【タイトル】特集 価値に基づく医療―患者にとっての最善の選択をめざして
・17.価値に基づく医療の実践―がん診療(山内 英子)

【タイトル】診療の秘訣
・早期大腸癌における癌間質線維化反応の有用性(岡本健太郎)

◆医薬経済 (1515号)/医薬経済社/発売日:2016年5月1日/価格(税込):2,160円
【タイトル】鳥集徹の口に苦い話=子宮頸がんワクチン「失敗」から学ぶべきこと(2)

Cancer Topics Index 05/02/2016(Daily Test version/ 日刊テスト版)No.21

konpas.jpg
Cancer Topics Index 05/02/2016(Daily Test version/ 日刊テスト版) No.21

Flags 【海外:overseas】
◇NCI (National Cancer Institute)◇
male-scientist-pouring-pink-media-article.jpg
【ブルーリボンパネルは、作業を開始】
The Cancer Community's Next Steps for the Moonshot Initiative (April 29, 2016 by Dinah Singer, Ph.D.)
At last week's annual meeting of the American Association for Cancer Research, Vice President Biden's historic address to more than 4,000 researchers in attendance made clear that he and President Obama agree with many of us in the research community: We are at a critical juncture where the convergence of expanded knowledge and a more detailed understanding of cancer, the availability of advanced technologies, and a national commitment to collaborating in new ways has produced an unprecedented opportunity for rapidly accelerating progress against cancer.

logo-clinicaltrials-gov.png
rinnsyo1.jpg
※2週間前の情報を基準として掲載。一部の記事(がんと直接関連しないもの)は割愛しています。
17 studies found for: cancer | received from 04/16/2016 to 04/18/2016

【乳がん】
1 Recruiting
Pink Warrior—Support Group Toolkit for Breast Cancer Survivors
Conditions: Breast Cancer; Physical Activity
Interventions: Behavioral: Active video game-based intervention; Behavioral: Pedometer
Sponsor:The University of Texas Medical Branch, Galveston
ClinicalTrials.gov Identifier:NCT02750241

【食道がん】
2 Recruiting
Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.
Conditions: Esophageal Cancer; Endostatin
Interventions: Drug: Endostatins; Drug: Oxaliplatin; Radiation: Radiotherapy
Sponsor:Hangzhou Cancer Hospital
ClinicalTrials.gov Identifier:NCT02745561

【神経芽腫】
3 Recruiting
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma
Conditions: Neuroblastoma; Neoplasms, Nerve Tissue
Interventions: Procedure: Autologous Hematopoietic Progenitor Cell Transplant; Biological: KLH and Tumor Lysate Pulsed DC Vaccine
Sponsor:H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:NCT02745756

【乳がん/リンパ浮腫】
4 Not yet recruiting
Reliability and Validity of Self-measured Arm Circumference in Women With Breast Cancer
Conditions: Lymphedema; Breast Cancer
Intervention: Procedure: Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference
Sponsor:University of British Columbia
ClinicalTrials.gov Identifier:NCT02752659

【がん/意思決定援助(PDA)】
5 Not yet recruiting
Development and Evaluation of a Fertility Preservation Patient Decision Aid for Women With Cancer.
Condition: Cancer
Intervention:
Sponsor:University of Sheffield
ClinicalTrials.gov Identifier:NCT02753296

【直腸がん】
6 Completed
Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer
Condition: Rectal Neoplasms
Interventions: Radiation: VMAT-SIB; Drug: XELOX
Sponsor:Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
ClinicalTrials.gov Identifier:NCT02745639

【血液がん】
7 Not yet recruiting
Phase I Trial of BAY1251152 for Advanced Blood Cancers
Condition: Hematologic Neoplasms
Intervention: Drug: BAY1251152
Sponsor:Bayer
ClinicalTrials.gov Identifier:NCT02745743

【大腸がん/マントル細胞リンパ腫】
8 Not yet recruiting
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Conditions: Advanced Cancer; Colorectal Cancer; Mantle Cell Lymphoma
Interventions: Drug: Ramucirumab; Drug: Merestinib; Drug: Abemaciclib
Sponsor:Eli Lilly and Company
ClinicalTrials.gov Identifier:NCT02745769

【膀胱がん】
9 Not yet recruiting
A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Sirolimus
Sponsor:The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:NCT02753309

【肝細胞がん】
10 Enrolling by invitation
DEB-TACE for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Procedure: DEB-TACE
Sponsor:Surefire Medical, Inc.
ClinicalTrials.gov Identifier:NCT02748161

【骨髄異形成症候群/急性骨髄性白血病】
11 Enrolling by invitation
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML
Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia
Interventions: Biological: NPMW-peptide vaccine; Drug: Azacitidine
Sponsor:Inge Høgh Dufva
ClinicalTrials.gov Identifier:NCT02750995

【乳がん/ER+ and AR+】
12 Not yet recruiting
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
Condition: ER+ and AR+ Breast Cancer
Intervention: Drug: GTx-024 9 or 18 mg
Sponsor:GTx
ClinicalTrials.gov Identifier:NCT02746328

【乳房切除術】
13 Completed
Paravertebral Block (PVB) Combined Pectoral Musculature Blocks for Modified Radical Mastectomy (MRM)
Condition: Mastectomy, Modified Radical
Intervention:
Sponsor:Sun Yat-sen University
ClinicalTrials.gov Identifier:NCT02747992

【造血幹細胞移植】
14 Not yet recruiting
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Acute Lymphocytic Leukemia
Interventions: Drug: Fludarabine; Radiation: Fractionated total body irradiation; Drug: Busulfan; Drug: Cyclophosphamide; Radiation: Single dose total body irradiation; Drug: Melphalan; Drug: Granulocyte-colony stimulating factor; Procedure: Stem cell transplant; Drug: Azacitidine
Sponsor:Washington University School of Medicine
ClinicalTrials.gov Identifier:NCT02750254

【びまん性大細胞型B細胞リンパ腫】
15 Recruiting
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: AZD 2014; Drug: Rituximab
Sponsor:University of Birmingham
ClinicalTrials.gov Identifier:NCT02752204

【頭頸部扁平上皮がん】
16 Not yet recruiting
Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: Cetuximab; Radiation: radiation; Drug: Docetaxel; Drug: Cisplatin
Sponsor:Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
ClinicalTrials.gov Identifier:NCT02753140

【造血幹細胞移植】
17 Active, not recruiting
Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Conditions: Myelodysplastic Syndrome; Allogeneic Hematopoietic Stem Cell Transplantation; Conditioning
Interventions: Drug: Decitabine; Drug: Busulfan (BU); Drug: Cyclophosphamide (CY)
Sponsor:Nanfang Hospital of Southern Medical University
ClinicalTrials.gov Identifier:NCT02744742

animated-european-union-flag.gif
◇EU, EMA, CHMP, Cancer Research UK, NICE◇
CannedFood_hero-hero.jpg
【News digest】
News digest – e-cigarettes, Chernobyl, ‘moonshots’ and… canned food? (April 30, 2016 Nick Peel Science blog)

<Medical Journal & Other News>
headline.jpg
【Hsp90阻害剤による薬剤耐性前立腺がんの治療】JOURNAL:Cancer Research
New cancer drugs could treat lethal resistant prostate cancers (05/01/2016 EurekAlert!/INSTITUTE OF CANCER RESEARCH)
Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.Researchers found that the drugs, called Hsp90 inhibitors, specifically target and inactivate a mechanism commonly used by prostate cancer cells to evade the effects of standard treatment.The findings provide vital information about the role of Hsp90 in drug-resistant prostate cancers, and open up potential new routes to cancer treatment based on blocking this or related proteins.

【ステージ第IIa精巣がん患者には、化学療法より放射線療法が効果的】JOURNAL:Clinical Oncology
Radiotherapy more effective than chemotherapy for early stage II testicular cancer (05/01/2016 EurekAlert!/EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY; ESTRO)
Turin, Italy: A large study of testicular cancer patients has shown that radiation therapy is a better treatment than chemotherapy for patients with stage IIa disease (where one or more regional lymph nodes contain cancer cells but they are less than 2cms in diameter).These findings, presented at the ESTRO 35 conference today (Monday) and published simultaneously in Clinical Oncology [1], are important because, until now, there has been little evidence about which treatment for testicular seminoma is more effective, and there has been a tendency to move away from radiation therapy towards chemotherapy for treating stage IIa-b patients. Guidelines from the US National Cancer Comprehensive Network recommend radiotherapy for stage IIa, while those from the European Association of Urology allow for either radiation therapy or chemotherapy; both sets of guidelines are equivocal for stage IIb.

【多発性骨髄腫】
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (April 28, 2016 The New England Journal of Medicine)
多発性骨髄腫に対する経口イキサゾミブ,レナリドミド,デキサメタゾン (April 28, 2016 Vol. 374 No. 17 南江堂洋書部:日本語)
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (First received: March 22, 2012 ClinicalTrials.gov Identifier:NCT01564537)

【Smart therapy】
がん細胞への攻撃を支援するソフトウェアを提供する新企業「ヴィトルヴィアン・ネットワークス」とは? (Apr 26, 2016 GE REPORTS JAPAN)
Vitruvian Networks (website)

【ロックと抗がん剤】
Thunderous rock music improves cancer drug delivery (1 April 2016 MNT)
ロックが抗がん剤の副作用を無くす? 音楽の新しすぎる可能性 (04/30/2016 CIRCL)

【睡眠時無呼吸症候群】
Sleep apnea may drive tumor growth by promoting blood vessel formation (12 March 2016 MNT)
新発見。睡眠時無呼吸症候群ががん細胞の増殖を許していた (05/01/2016 CIRCL)

Graphics 【日本国内:Japan】
<Press Release:日本国内>
【がん検診アンケート調査】
癌の検診に対しての意識を調査、どのようながん検診・検査を受けている人が多いのか? (04/30/2016 iMedi)

<News>
【心臓腫瘍】
ひたむきに生きて サッちゃんに教わった=天野篤・順天堂医院院長 (05/01/2016 毎日新聞)

【腫瘍溶解ウイルス】
img_bfe074c5936246f352c21ec5f2399e02210033.jpg
オンコリスが苦難を越えて実現目指す、がん細胞を溶かす治療薬(上)(04/30/2016 会社四季報Online)

【患者格差】
日本人の9割は2流? “患者格差”はどこで生まれるのか テキサス大学MDアンダーソンがんセンター上野直人医師 (04/29/2016 dot.)

【在宅医療】
「"死ぬまで、どう生きるか"を選択しよう」佐々木淳さんに聞く、これからの在宅医療 (04/29/2016 ハフィントン・ポスト)

<新刊メタデータ:New Books>
book_sepia.jpg
【タイトル】がん放置実践実録 Vol.2 (乳がん)
著者:久保園 和巳/単行本(ソフトカバー): 112ページ/出版社: ブイツーソリューション (2016/4/30)/ISBN-10: 4864764026/ISBN-13: 978-4864764025/¥432

【タイトル】白い洋梨 Kindle版 (小説)
著者:時枝 文彦/フォーマット: Kindle版/ファイルサイズ: 65536 KB/同時に利用できる端末数: 無制限/販売: Amazon Services International, Inc./ASIN: B01F1NH7A6/¥510

<雑誌記事:Magazine/Medical journal>
Stockholm Public Library
◆月刊薬事 (Vol.58 No.7)/じほう/発売日:2016年4月30日/価格(税込):2,160円
【タイトル】特集 薬剤師目線で実践する経口抗がん薬マネジメント
 気になる新薬マネジメント、がん患者指導管理や薬薬連携のコツを紹介!
・特集にあたって  遠藤 一司
・経口抗がん薬――分類とその特徴について  石川 和宏
・アファチニブの特徴と薬学的管理のポイントは?  浅野 裕紀
・レンバチニブの特徴と薬学的管理のポイントは?  鈴木 真也
・トリフルリジン・チピラシルの特徴と薬学的管理のポイントは?  秋山 加菜
・ニボルマブの特徴と薬学的管理のポイントは?  池見 泰明、山本 将太、松原 和夫
・がん患者指導管理はどうやって始めればよい?
 薬剤師外来でのがん患者指導管理料3算定への取り組み  川澄 賢司
 薬剤師外来の運用と有用性の評価  小川 千晶
 診察前面談における副作用のモニタリングとアセスメント  組橋 由記
・上手くいく薬薬連携のコツは?
 FAXを活用した双方向性の情報共有  黒岩 勇人、眞継 賢一、上田 綾佳、倉橋 基尚、濱口 良彦
 がん化学療法支援ツールの共有による地域の薬薬連携  谷沢 克弥
 情報共有ツールの活用と学習課題を明確化した勉強会  竹内 雅代
 薬局から始める取り組みで外来化学療法のサポートを  笹本千香子

◆臨床栄養 (Vol.128 No.5)/医歯薬出版/発売日:2016年4月30日/価格(税込):1,620円
【タイトル】スポット
・緩和ケア病棟における進行がん患者と家族の栄養サポートに対するニーズ,食に関する苦悩と体験 天野晃滋

◆日経ヘルス (2016年6月号)/日経BP社/発売日:2016年4月30日/価格(税込):600円
【タイトル】がん予防の基礎講座
・がんと遺伝 遺伝性が多い乳がん、卵巣がん リスクを理解し、検診を受けよう


上記広告は1ヶ月以上更新のないブログに表示されています。新しい記事を書くことで広告を消せます。